Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 15;45(2):37-46.
doi: 10.2478/prilozi-2024-0014. Print 2024 Jun 1.

Aspirin Resistance and Ischemic Stroke

Elena Lichkova  1   2 , Valentina Velkoska Nakova  1   2 , Anita Arsovska  3 , Meri Shorova  2   4 , Daniela Ristikj Stomnaroska  2   5
Affiliations

Aspirin Resistance and Ischemic Stroke

Elena Lichkova et al. Pril (Makedon Akad Nauk Umet Odd Med Nauki). .

Abstract

Objective: Acetylsalicylic acid (ASA) is the most widely used antiplatelet agent in treating ischemic strokes. ASA resistance varies between the populations, from 5% to 60%. We aimed to determine the prevalence of ASA resistance in our population, its association with demographic characteristics, risk factors, and the occurrence of recurrent ischemic stroke (IS). (IST). Methods: One hundred consecutive patients with primary or recurrent IS were prospectively included. Strokes were diagnosed with computed tomography (CT) or magnetic resonance imaging (MRI). In all patients a detailed history of cardiovascular risk factors and fasting blood analyzes (blood count, glycemia, HbA1c, degradation products, lipid profile) were taken, and the ASA resistance was examined with the Innovance PFA 200 system. The ASA resistance was examined after a minimum of 1 month of regular use of ASA 100 mg per day. Results: The prevalence of ASA resistance was 32%. ASA-resistant patients were statistically significantly older (69.9±7.5 vs, 61±1 y., p<0.05), and of male gender (75 vs, 45.6%, p<0.05). Previous cardiovascular diseases were statistically significantly more common in the ASA-resistant patients compared to the ASA-sensitive patients (46.8 vs 26.5%, p<0.05). The presence of recurrent stroke in the ASA-resistant versus ASA-sensitive patients was statistically significant (75% vs. 22.05%, p<0.0001). There was no statistically significant difference in the investigated laboratory parameters and the risk factors between the ASA-resistant and the ASA-sensitive patients. Conclusion. The prevalence of ASA resistance in our population is high. According to our results, ASA resistance testing should be done in the older male individuals with a previous burden of cardiovascular diseases.

Keywords: ASA resistance; ischemic stroke; recurrent stroke.

PubMed Disclaimer

References

    1. Manojna Konda, MD University of Arkansas. GBD Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20:795–820. doi:10.1016/S1474-4422(21)00252-0.
    1. Schlemm L. Disability Adjusted Life Years due to Ischaemic Stroke Preventable by Real-Time Stroke Detection-A Cost-Utility Analysis of Hypothetical Stroke Detection Devices. Front Neurol. 2018;9:814. doi: 10.3389/fneur.2018.00814.
    1. Yatsu FM, Yamaguchi T, Norrving B. International aspects of global stroke burden. Int J Stroke. 2006;1(4):222-3. doi: 10.1111/j.1747-4949.2006.00067.x.
    1. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F. The global stroke initiative. Lancet Neurol. 2004;3(7):391-3. doi: 10.1016/ S1474-4422(04)00800-2.
    1. Rothlisberger JM, Ovbiagele B. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness. J Comp Eff Res. 2015;4(4):377-84. doi: 10.2217/cer.15.22.